NVS - Novartis blood disorder drug Fabhalta not better than current treatment - ICER
2024-03-13 18:56:55 ET
More on Novartis
- Novartis And MorphoSys Are A Perfect Match
- Novartis AG (NVS) Q4 2023 Earnings Call Transcript
- Novartis AG 2023 Q4 - Results - Earnings Call Presentation
- Novartis to pay up to $835M for STING antagonist developer IFM Due
- Radiopharmaceutical market expected to reach ~$14B by 2032